Acuitas Therapeutics v. CureVac SE: Patent Infringement Case Transferred in 15 Days
Acuitas Therapeutics and four co-inventor plaintiffs filed a patent infringement action against CureVac SE in the Eastern District of Virginia, asserting four US patents covering lipid nanoparticle (LNP) technology in coronavirus vaccines. The court transferred the case to the Norfolk Division within 15 days, consolidating it with a related BioNTech SE v. CureVac SE action before Judge Walker.
LNP vaccine patent dispute routed to Norfolk for consolidated CureVac litigation
On 13 November 2023, Acuitas Therapeutics, Inc. together with named inventors Barbara Mui, Paulo Lin, Ying Tam, and Michael Hope filed a patent infringement action in the Eastern District of Virginia against CureVac SE. The complaint asserted four US patents — US11576966B2, US11596686B2, US11241493B2, and US11471525B2 — all directed to lipid nanoparticle delivery technology applied in coronavirus vaccines. McGuireWoods LLP represented the plaintiffs; no defendant counsel of record appears in the available docket.
The recorded basis of termination is Case Transferred. The docket order states that the court, acting sua sponte in the interest of judicial efficiency, directed the Clerk to transfer the case to the Norfolk Division and to assign it directly to Judge Jamar K. Walker, who was already presiding over the related matter BioNTech SE v. CureVac SE, case no. 2:23cv222. This reassignment occurred within 15 days of filing, before any substantive ruling on the merits.
The transfer suggests the court identified a material overlap between this action and the pre-existing BioNTech v. CureVac litigation, making consolidated case management before a single judge the more efficient path. The specific claims asserted, any claim construction positions, and the underlying infringement theory are not detailed in the available transfer order. How the consolidated proceedings before Judge Walker are structured, and whether the two actions will be formally joined or merely coordinated, is not disclosed in the public record at this stage.
See Complete Case & Patent Analysis →Filing to Case Transferred in 15 days
Case resolved by transfer in 15 days — before any substantive hearing on the merits
US11576966B2 and three further LNP coronavirus vaccine patents
Any organisation developing, manufacturing, or commercialising lipid nanoparticle formulations for mRNA delivery — whether for vaccines, oncology, or other therapeutic indications — should treat the Acuitas patent portfolio as a mandatory FTO priority. The four patents asserted in this case represent a subset of a broader LNP estate, and the active enforcement posture demonstrated here signals that Acuitas is prepared to pursue litigation to protect its IP position.
Official order — verbatim text
The transfer order was issued sua sponte and addresses only case administration — it makes no finding on infringement, validity, or any substantive patent issue. The court's sole stated basis was judicial efficiency, citing Judge Walker's existing assignment of the related BioNTech v. CureVac matter. All merits questions remain open and will be determined in the Norfolk Division.
What a sua sponte transfer means for this case
A sua sponte transfer means the court acted on its own initiative — without a motion from either party — to reassign the case. Under 28 U.S.C. § 1404 principles, courts may transfer for the convenience of parties and witnesses or in the interest of justice. Here, the driver was judicial efficiency: a related CureVac action was already pending before Judge Walker in Norfolk. No merits ruling was made.
No merits adjudicationNorfolk Division: what the transfer changes for the parties
The case moves from its originally filed division to the Norfolk Division of the Eastern District of Virginia — still within the same district court. Judge Walker, already familiar with CureVac's technology and defences from the BioNTech case, will now hear both actions. This typically means shared scheduling, potential coordinated discovery, and a single judge resolving common legal questions across both suits.
Consolidated before Judge WalkerCase continues in Norfolk alongside BioNTech v. CureVac
The transfer is not a dismissal — all four asserted patents remain live in the litigation. The action now proceeds before Judge Walker as case no. 2:23cv222 or a related docket. Parties will be expected to appear in the Norfolk Division for all future proceedings. Whether the two CureVac actions will be formally consolidated or simply coordinated is not disclosed in the available transfer order.
Litigation ongoing in NorfolkMulti-plaintiff infringement action signals coordinated LNP enforcement
The inclusion of four named inventors alongside the corporate plaintiff Acuitas Therapeutics is consistent with strategies to establish standing across all ownership interests. Filing in parallel with BioNTech's related suit against CureVac suggests a coordinated enforcement front in the LNP vaccine IP space. The consolidation before one judge may accelerate resolution of common claim construction issues relevant to both actions.
Coordinated LNP enforcementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Acuitas Therapeutics, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Barbara Mui | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Paulo Lin | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Ying Tam | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Michael Hope | Individual | Search in Eureka ↗ |
| Defendant | Curevac SE | Individual | /Search in Eureka ↗ |
| Plaintiff counsel | Robert William McFarland | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McGuireWoods LLP | Law Firm | Representing Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge M. Hannah Lauck | Judge | Virginia Eastern District CourtSearch in Eureka ↗ |
R&D signals in the lipid nanoparticle and mRNA vaccine IP space
Forward-looking patent and innovation intelligence derived from the Acuitas–CureVac dispute and the broader LNP delivery technology landscape.
Acuitas Therapeutics' LNP patent filing activity
Acuitas asserted four patents with application dates clustered in 2021–2022, suggesting an active continuation filing strategy post-COVID vaccine approval. Monitoring Acuitas's pending applications and continuation chains is critical for any company developing LNP-based mRNA therapeutics — new claims may expand coverage beyond what the issued patents reflect.
Active continuation strategyLNP formulation patent filing trends since 2020
The mRNA vaccine era triggered a surge in LNP-related patent filings from multiple assignees including Acuitas, Moderna, Arbutus, Alnylam, and Precision BioSciences. Understanding filing density and claim overlaps across these portfolios helps R&D teams identify freedom-to-operate risks and white-space opportunities in LNP ionisable lipid design.
High filing density post-2020CureVac SE's patent position in LNP and mRNA delivery
CureVac is defending against coordinated LNP infringement actions from both Acuitas and BioNTech. Analysing CureVac's own patent filings in mRNA delivery and LNP formulation may reveal defensive assets, cross-licence leverage, or gaps in their IP strategy that are relevant to competitors and potential partners in the mRNA therapeutics space.
Dual-front defensive postureAdjacent LNP design space beyond Acuitas claim coverage
With multiple LNP patent estates now actively enforced, R&D teams should map adjacent ionisable lipid structures, helper lipid ratios, and PEGylation approaches not covered by the Acuitas or Arbutus claim sets. Eureka's landscape analysis can identify structurally distinct LNP compositions that may represent lower-risk development paths for next-generation mRNA therapeutics.
LNP design white spaceRelated LNP and mRNA vaccine patent infringement cases in US federal courts
Explore patent infringement actions involving lipid nanoparticle and mRNA vaccine technology in the Eastern District of Virginia and related US federal courts.
What this case signals for the mRNA vaccine LNP IP landscape
Multiple plaintiffs targeting CureVac in the same court signals intensifying enforcement around lipid nanoparticle delivery technology.
LNP delivery IP is a multi-front enforcement battleground
Acuitas's four-patent assertion against CureVac, filed concurrently with BioNTech's related action, indicates that LNP technology ownership is actively and aggressively contested across the mRNA vaccine sector. Companies operating in this space should map their own LNP formulation methods against the Acuitas and BioNTech portfolios.
Judicial consolidation accelerates shared claim construction risk
With both CureVac actions now before a single judge, any claim construction ruling on LNP-related terms will simultaneously affect Acuitas's and BioNTech's positions. Parties monitoring this litigation should track Judge Walker's rulings for early signals on how key LNP patent claims will be interpreted.
Acuitas v Curevac — key questions answered
Acuitas Therapeutics asserted four US patents: US11576966B2, US11596686B2, US11241493B2, and US11471525B2. All are directed to lipid nanoparticle delivery technology applied to coronavirus vaccines. The corresponding application numbers are US17/526912, US17/818699, US17/231261, and US17/546414.
The court acted sua sponte in the interest of judicial efficiency. Judge Walker in the Norfolk Division was already presiding over a related action, BioNTech SE v. CureVac SE (2:23cv222). Consolidating both CureVac cases before one judge was the court's stated rationale. No motion by either party prompted the transfer.
Both cases involve patent infringement claims against CureVac SE relating to coronavirus vaccine technology. The court identified them as related and transferred the Acuitas action to the same division and judge — Judge Walker — handling the BioNTech case (2:23cv222). The specific overlap in patents or technology between the two suits is not detailed in the available transfer order.
The complaint lists Barbara Mui, Paulo Lin, Ying Tam, and Michael Hope as co-plaintiffs alongside Acuitas Therapeutics. Naming individual inventors as co-plaintiffs is consistent with ensuring all parties with ownership interests are joined to establish complete standing. The specific assignment or ownership structure underlying this choice is not detailed in the available public record.
No. The case was transferred just 15 days after filing. The transfer order addresses only case administration and consolidation with the related BioNTech v. CureVac action. No ruling on infringement, validity, claim construction, or any other substantive patent issue was made in this case prior to transfer.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.